Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
(Date:7/29/2014)... WASHINGTON , July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. ...
(Date:7/29/2014)... July 29, 2014 Numotion,s Board of Directors has ... will be the company,s new Chief Executive Officer. ... career at GE where he worked primarily for GE Healthcare ... to over $5 billion. His most recent position was as ... "I am thrilled to join Numotion," said Mike ...
Breaking Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2
... 3, 2011 Nonin Medical, Inc., the inventor of ... a leader in noninvasive physiological monitoring, announced the worldwide ... Pulse Oximeter for medical monitoring manufacturers. ... wired pulse oximeter will provide a new level of ...
... Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) ... Senior Vice President of Research and Development, Cynthia Schwalm ... M.D., as Senior Vice President of Pharmacovigilance. These newly ... the Company prepares for the potential launch of its ...
Cached Medicine Technology:Nonin Medical Launches Low Power Xpod®, Model 3012LP, OEM Pulse Oximeter Globally 2Optimer Pharmaceuticals Expands Senior Management Team 2Optimer Pharmaceuticals Expands Senior Management Team 3Optimer Pharmaceuticals Expands Senior Management Team 4Optimer Pharmaceuticals Expands Senior Management Team 5
(Date:7/30/2014)... The Diabetes Daily Grind had its beginnings ... Ryan Fightmaster hope to gain attention for the website ... 26th of this year, Clour and Fightmaster started this ... diabetic life. By sharing stories on their lessons ... other diabetics will find ways to live with their ...
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review recently ... people how to cure their nasal polyps permanently ... horrible truth about conventional treatments for nasal polyps. , ... will learn how to prevent symptoms related to nasal ... Nasal Polyps Treatment Miracle, as it is reviewed now by ...
(Date:7/30/2014)... The San Diego personal injury lawyers of The ... they are now offering free case reviews for individuals that ... , “Symptoms of asbestos exposure can take years to develop, ... years ago may just now be suffering from the ill ... Melinda J. Helbock A.P.C. “We want people to know that ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nuanced Media, a ... announce the release of the Medical Web Design Trends of ... of research done across multiple agencies and the medical web ... are constantly changing as the industry grows. Therefore it is ... of ideas that consumers enjoy most. New trends are defined ...
(Date:7/29/2014)... 30, 2014 Saint Luke’s Medical ... awarded the Patient-Centered Medical Home 2011 Level 3 ... for Quality Assurance. Only one out of four ... Level 2, or Level 3 recognition. , Patients ... Medical Home report faster access to their doctors, ...
Breaking Medicine News(10 mins):Health News:Strangers Come Together to Form Diabetes Website: Real Messages of Hope and Inspiration 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2
... of the disease among those vaccinated were no higher ... (HealthDay News) -- Rates of a rare neurodegenerative disease, ... last year were no higher than among the general ... syndrome were noted after widespread swine flu vaccination in ...
... April 13, 2010 Allergies have become a widespread ... are all increasingly prevalent. The reason? Excessive cleanliness is ... at the Universit de Montral Faculty of Medicine. ... pollution, processed foods, stress, tobacco use, etc. Yet our ...
... 2010) The human mouth is home to an estimated ... moist environment, along with hard tooth surfaces and soft tissues, ... of these bacteria are harmful and can form a film ... eventually more severe kinds of gum disease. Toothpaste ...
... ... features and prices of March special SEO offers, SEO-Peace.com management is pleased to extend its ... features to the client base. , ... Gurgaon, India (PRWEB) April 13, 2010 -- With SEO industry getting more and more ...
... , ... 1 out of every 6 men in the United States (1 in 3 in the ... against prostate cancer by registering for Little Red Door,s Unite 2 Fight Race Against Prostate ... Indianapolis, IN (PRWEB) ...
... with Williams syndrome have no social fear and appear ... 13 (HealthDay News) -- Children with a rare ... and with it, racial prejudice, a new study shows. ... the root cause of racial stereotyping. , French and ...
Cached Medicine News:Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 2Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 3Health News:Why are allergies increasing? 2Health News:Give dirty mouths a brush 2Health News:SEO-Peace.com Extends The March Special SEO Special Offers And Revise Many Services 2Health News:Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010 2Health News:Kids With Rare Condition Lack Racial Prejudice 2
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: